Cardiac risk in the treatment of breast cancer: assessment and management

Antonis Valachis,1 Cecilia Nilsson2 1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden Abstract: As the number of long-term breast cancer survivors has in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Valachis A, Nilsson C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/ab8433f1ba2449d19c6062e18f76802a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ab8433f1ba2449d19c6062e18f76802a
record_format	dspace
spelling	oai:doaj.org-article:ab8433f1ba2449d19c6062e18f76802a2021-12-02T00:29:08ZCardiac risk in the treatment of breast cancer: assessment and management1179-1314https://doaj.org/article/ab8433f1ba2449d19c6062e18f76802a2015-01-01T00:00:00Zhttp://www.dovepress.com/cardiac-risk-in-the-treatment-of-breast-cancer-assessment-and-manageme-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314 Antonis Valachis,1 Cecilia Nilsson2 1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden Abstract: As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities. Keywords: adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumabValachis ANilsson CDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 21-35 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Valachis A Nilsson C Cardiac risk in the treatment of breast cancer: assessment and management
description	Antonis Valachis,1 Cecilia Nilsson2 1Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden; 2Center for Clinical Research, Västmanlands County Hospital, Västerås, Sweden Abstract: As the number of long-term breast cancer survivors has increased, the side effects of adjuvant cancer therapy, such as cardiac toxicity, remain clinically important. Although the cardiac toxicity due to anthracyclines, radiotherapy, or trastuzumab is well-documented, several issues need to be clarified and are the subjects of extensive ongoing clinical research. This review summarizes the incidence of cardiac toxicity due to breast cancer adjuvant therapy and highlights the current trends in early detection and management of cardiac toxicities. Keywords: adjuvant, anthracyclines, cardiac toxicity, radiotherapy, trastuzumab
format	article
author	Valachis A Nilsson C
author_facet	Valachis A Nilsson C
author_sort	Valachis A
title	Cardiac risk in the treatment of breast cancer: assessment and management
title_short	Cardiac risk in the treatment of breast cancer: assessment and management
title_full	Cardiac risk in the treatment of breast cancer: assessment and management
title_fullStr	Cardiac risk in the treatment of breast cancer: assessment and management
title_full_unstemmed	Cardiac risk in the treatment of breast cancer: assessment and management
title_sort	cardiac risk in the treatment of breast cancer: assessment and management
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/ab8433f1ba2449d19c6062e18f76802a
work_keys_str_mv	AT valachisa cardiacriskinthetreatmentofbreastcancerassessmentandmanagement AT nilssonc cardiacriskinthetreatmentofbreastcancerassessmentandmanagement
_version_	1718403698635309056

Cardiac risk in the treatment of breast cancer: assessment and management

Ejemplares similares